Edesa Biotech, Inc. Common Shares
Veridion Score
Composite trend over time
Why is EDSA moving today?
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for EDSA.
EDSA insider activity
Edesa Biotech, Inc. Common Shares
No multi-insider buying cluster in the last 90 days
Net buying: $1.0M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-16 | 2026-06-16 | Nijhawan Pardeep | Insider | buy | $5.21 | 153,550 | 884,684 | $800K | SEC Form 4 |
| 2026-03-11 | 2026-02-26 | Brooks Michael J | Insider | buy | $1.57 | 2,000 | 226,870 | $3K | SEC Form 4 |
| 2026-03-10 | 2026-03-10 | Nijhawan Pardeep | Insider | buy | $6.60 | 1,000 | 628,813 | $7K | SEC Form 4 |
| 2026-03-06 | 2026-03-05 | Nijhawan Pardeep | Insider | buy | $3.90 | 10,000 | 402,702 | $39K | SEC Form 4 |
| 2026-03-05 | 2026-03-04 | Nijhawan Pardeep | Insider | buy | $4.26 | 10,000 | 392,702 | $43K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 5 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moEDSA contract awards, year to date.
Public federal awards linked to this ticker.
EDSA lobbying filings, year to date.
Registered lobbying filings matched to Edesa Biotech, Inc. Common Shares.